Longevity Interest Spans Health, Medicine, Investment

Interest in longevity is expanding, but experts caution that biological-age scores, supplements and other wellness trends are meaningful only when they address measurable risks such as cardiovascular disease, metabolic illness, cancer or dementia. Personalized testing—including blood work, genetic sequencing and assessments of strength and function—may help identify risks before symptoms appear, though its value depends on translating results into practical interventions. For facial aging, a leading plastic surgeon emphasizes foundational skin care and restrained, age-appropriate treatments, warning that “prejuvenation” procedures and collagen-focused interventions can be oversold. A New Delhi symposium organized by ODDS Longevity likewise focused on the symptom-free years when metabolic and mechanical decline may begin, bringing together medical, exercise and nutrition specialists to discuss prevention. Meanwhile, Singapore-based Immortal Dragons is directing a $40 million fund toward early-stage longevity biotechnology, particularly replacement strategies, gene therapies, brain rejuvenation and other high-risk approaches intended to replace failing biological functions rather than merely repair them.